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IntroductIon
Epithelial–mesenchymal interactions play an important role 
in the control of normal tissue homeostasis and carcino-
genesis (Bissell and Hines, 2011; Junttila and de Sauvage, 
2013). Changes in tumor stroma, such as induction of can-
cer-associated fibroblasts (CAFs) and associated chronic in-
flammation, are most frequently viewed as secondary to 
changes in the epithelium. However, recent evidence indi-
cates that they may play a concurrent or even primary role in 
cancer initiation and progression (Dotto, 2014).
Field cancerization—multifocal and recurrent tu-
mors with broader changes of surrounding tissues—is a 
frequent clinical occurrence in many organs, such as the 
skin, head/neck, lung, breast, prostate, and colon (Dotto, 
2014). It is very difficult to treat, and greater insights 
into how it develops are urgently needed. We have de-
veloped a mouse model of skin field cancerization based 
on mesenchymal deletion of the Csl gene, the key effec-
tor of canonical Notch signaling (Hu et al., 2012). CSL, a 
DNA-binding protein with intrinsic transcription repres-
sive function, negatively regulates many genes with CAF 
effector functions, encoding mitogenic growth factors, 
proinflammatory cytokines, and matrix remodeling pro-
teins (Hu et al., 2012; Procopio et al., 2015). In addition, 
CSL physically interacts with p53, suppressing its activ-
ity, and escape from p53-induced stromal cell senescence, 
resulting from loss of CSL, is part of a cancer-associated 
stromal cell evolution process (Procopio et al., 2015). The 
transcription/chromatin modification events that converge 
with compromised CSL function in the early steps of CAF 
activation are as yet unknown.
ATF3, a stress response transcription factor of the AP1/
CREB family, has been extensively studied in cells of immune 
and inflammatory systems (Thompson et al., 2009). Increased 
Atf3 expression plays an important role in oncogenic conver-
sion of keratinocytes, as it occurs in the skin of organ graft re-
cipients being treated with calcineurin inhibitor drugs (Wu et 
al., 2010). The role of ATF3 in dermal fibroblasts has not yet 
been explored. We report herein that ATF3 converges with 
CSL in negative control of CAF activation. Compromised 
expression of either gene results in strikingly similar chroma-
tin modifications and changes in gene expression, which can 
be counteracted by bromodomain and extra-terminal (BET) 
inhibitors in vitro and in vivo.
cancer-associated fibroblasts (cAFs) are important for tumor initiation and promotion. cSL, a transcriptional repressor and 
notch mediator, suppresses cAF activation. Like cSL, AtF3, a stress-responsive transcriptional repressor, is down-modulated 
in skin cancer stromal cells, and Atf3 knockout mice develop aggressive chemically induced skin tumors with enhanced cAF 
activation. Even at low basal levels, AtF3 converges with cSL in global chromatin control, binding to few genomic sites at a 
large distance from target genes. consistent with this mode of regulation, deletion of one such site 2 Mb upstream of IL6 
induces expression of the gene. observed changes are of translational significance, as bromodomain and extra-terminal (BEt) 
inhibitors, unlinking activated chromatin from basic transcription, counteract the effects of AtF3 or cSL loss on global gene 
expression and suppress cAF tumor-promoting properties in an in vivo model of squamous cancer–stromal cell expansion. thus, 
AtF3 converges with cSL in negative control of cAF activation with epigenetic changes amenable to cancer- and stroma- 
focused intervention.
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rESuLtS
Atf3 deficiency promotes dysplastic skin 
tumors and cAF activation
The role of ATF3 in dermal fibroblasts has not been inves-
tigated. UVA, a main cause of skin cancer, can directly af-
fect cells of the dermal compartment (Bachelor and Bowden, 
2004). Atf3 expression was induced in primary human der-
mal fibroblasts (HDFs) soon after UVA treatment at doses 
equivalent to 2 h of sunlight exposure (Fig. S1, A and B; Bal-
asaraswathy et al., 2002), a finding validated by immunoflu-
orescence (IF) analysis of UVA-treated human skin explants 
(Fig. S1 C). Atf3 up-regulation was transient and inversely 
related to Csl expression, which is down-modulated by UVA 
exposure of HDFs (Fig. S1 D; Menietti et al., 2016).
Actinic keratoses (AKs) are precancerous lesions that 
develop in photo-damaged skin. Laser capture microdissec-
tion (LCM) followed by RT-qPCR analysis showed signifi-
cant down-modulation of Atf3 expression in AK-underlying 
dermal cells versus cells from surrounding unaffected skin, 
similarly to decreased Csl (Fig. 1 A; Procopio et al., 2015). In 
situ skin squamous cell carcinomas (SCCs) have greater cel-
lular abnormalities than AKs, which extend to all epidermal 
layers. Although there is not yet invasion, alterations of dermal 
tissue are likely to occur as part of expanding cancer fields 
(Dotto, 2014). LCM analysis showed decreased Atf3 expres-
sion in stromal fibroblasts underlying in situ SCCs relative to 
those in flanking skin of the same patients and, to a greater 
extent, of other individuals (Fig. 1 B). Leukocyte and endo-
thelial cell contaminations in tested samples were ruled out by 
previous analysis with corresponding markers and the use of 
anti-PDG FRα antibodies for fibroblast identification before 
capture (Procopio et al., 2015). Results were further validated 
in mice with mesenchymal deletion of the Csl gene (Hu et 
al., 2012). LCM and RT-qPCR analysis showed significant 
down-modulation of stromal Atf3 expression in keratinocyte 
lesions that developed in these mice at 3 mo of age relative to 
distant unaffected skin (Fig. 1 C).
To assess the functional significance of decreased Atf3 
expression, we assessed susceptibility of mice with and without 
deletion of the Atf3 gene (Hartman et al., 2004) to skin chemi-
cal carcinogenesis. The fraction of Atf3−/− mice that developed 
tumors was slightly less than that of the controls in one exper-
iment, with no significant difference in another (Fig. S1 E). 
Importantly, Atf3−/− mice developed a much higher fraction of 
dysplastic lesions than controls and, over the tested time frame, 
were the only ones to have invasive, at times ulcerative, SCCs 
(Fig. 1 D and Fig. S1 F). Expression of terminal differentiation 
markers such as loricrin was strongly reduced in tumors formed 
in Atf3−/− mice (Fig. 1 E), with basement membrane fragmen-
tation and massive up-regulation of matrix metalloprotease 1 
(MMP1) in tumor stroma (Fig. 1, F and G). IL6, a proinflam-
matory and protumorigenic cytokine, and tenascin C (TNC), 
a cancer-associated matrix protein, were highly expressed in 
the tumor-surrounding stroma of Atf3−/− mice and also in the 
dermis farther away (Fig. 1, H and I; Fig. S1, G and H).
To focus on intrinsic consequences of Atf3 deletion in 
dermal fibroblasts, we derived these cells from mice with and 
without Atf3 deletion and from mice with the “floxed” Atf3 
gene (Wolford et al., 2013) followed by in vitro deletion via 
infection with a Cre-expressing adenovirus. In both cases, 
Atf3 gene deletion resulted in pronounced up-regulation of 
various CAF effector genes, encoding growth factors and cy-
tokines, matrix proteins, and MMPs (Fig.  2, A and B). For 
in vivo significance, we used a cancer–stromal cell expansion 
assay (Procopio et al., 2015) with parallel mouse ear injec-
tions of dermal fibroblasts with and without Atf3 deletion 
admixed with weakly tumorigenic skin SCC cells (SCC13) 
expressing DsRed2. Analysis of red fluorescence surface area 
and signal intensity at daily intervals showed greater expan-
sion of SCC13 cells admixed with Atf3-deficient compared 
with control fibroblasts (Fig. 2, C and D). Two of five mice 
injected with Atf3−/− dermal fibroblasts developed ulcer-
ative tumors with disruption of the ear epidermis, whereas 
no such ulcerations arose in contralateral lesions. Histological 
analysis showed greater tumor cell density in lesions formed 
together with Atf3−/− fibroblasts with a higher fraction of 
phospho-H3–positive tumor cells (Fig. 2, E and F; and Fig. 
S1, I and J). MMP1 expression was much more pronounced 
in the stromal region of these tumors (Fig. 2 G and Fig. S1 K), 
and vessel density, as assessed by CD31 immune staining, was 
significantly increased (Fig. 2 H).
As a complement, dermal fibroblasts with and without 
Atf3 deletion were admixed with either SCC13 cells or a 
mouse skin SCC line (PAM212) followed by intradermal in-
jections into mouse back skin. Even under these conditions, 
tumors formed in the presence of Atf3-deficient fibroblasts 
exhibited greater cellularity, with reduced squamous differen-
tiation, an increased proliferative index, and higher IL6 stro-
mal expression (Fig. S1, L–O).
overlapping transcription repressive function of AtF3 and 
cSL on cAF effector genes
The ATF3 transcription repressive function may overlap with 
that of CSL. Increased Atf3 expression by lentiviral vector 
infection, to levels comparable to those induced by UVA 
(Fig. S1 B), caused suppression of various CAF-related genes 
(Fig. 3 A) that are under negative CSL control (Procopio et 
al., 2015). For global assessment, we combined RNA-seq and 
ChIP-seq analysis of HDFs with and without increased ATF3 
expression and compared the results with those for CSL (Pro-
copio et al., 2015). In cells with increased ATF3, 662 mod-
ulated genes were direct ATF3 targets, with 102 also being 
under direct CSL control (Fig. 3 B and Table S1). ATF3 and 
ATF3/CSL–regulated genes were significantly enriched for 
families related to cell adhesion–matrix interactions, devel-
opment, and proliferation (P < 0.05; Fig. 3 C and Table S2). 
Direct ATF3 and CSL targets included many genes of bio-
logical significance, coding for growth factors and cytokines, 
cancer-associated matrix proteins, tyrosine kinase receptors, 
and transcription factors, including Csl itself (Fig. 3 D).
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Figure 1. Atf3 deficiency promotes dysplastic keratinocyte tumor development and widespread stromal alterations. (A) Laser-captured micro-
dissection (LCM) and RT-qPCR analysis of Atf3 expression in actinic keratosis (AK)–underlying stromas (n = 7) and matched flanking normal skin stromas 
(normal; n = 7) from patients using 36β4 normalization. Data are mean ± SEM, two-tailed paired t test, *, P < 0.05. (B) LCM followed by RT-PCR analysis 
of Atf3 expression in PDG FRα-positive cells from stroma underlying in situ SCC lesions (n = 5) versus flanking skin (n = 5) and dermis (n = 6) from other 
individuals (face and abdomen derived; black and gray circles) using β−actin for normalization. Data are mean ± SEM, two-tailed unpaired t test, *, P < 0.05. 
(C) LCM and RT-qPCR analysis of Atf3 expression in stromal cells from three skin lesions (two areas per lesion: A and B) versus matching stroma of 
unaffected skin in mice with mesenchymal Csl deletion. n = 6 affected regions and three unaffected regions, ratio log10(lesion/unaffected), two-tailed 
one-sample t test, *, P < 0.05. The same samples were previously analyzed for possible leukocyte contamination (Procopio et al., 2015). (D) Two independent 
experiments with mice with and without Atf3 gene deletion subjected to a multistep skin chemical carcinogenesis protocol over 25 wk. Time of appearance, 
incidence, and number of tumors are shown in Fig. S1 E. n = 20 tumors from eight Atf3+/+ mice n = 22 tumors from 7 Atf3−/− mice for the first experiment; 
n = 32 tumors from 8 Atf3+/+ mice and n = 26 tumors from 9 Atf3−/− mice for the second experiment. Two-tailed χ2 test, *, P < 0.05. N/D, not detected; ns, 
not significant. The left panels are a quantification of the histological results expressed as percentages of the total number of analyzed tumors per genotype. 
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ATF3 and CSL binding peaks on common target genes 
and at the global genomic level were mostly separate from 
each other (Fig. 3 E and Table S3), suggesting that the two 
factors do not directly interact but function in concert with 
other regulators of transcription. In fact, motif enrichment 
analysis (MEA) showed frequent overlapping of ATF3 and 
CSL binding with recognition sequences for different sets of 
transcription factors with which these proteins are known 
to associate, such as Jun and Fos family members for ATF3 
(Thompson et al., 2009) and MEF2C for CSL (Shen et al., 
2006; Fig. 3 F). A fraction of CSL or ATF3-binding regions 
shared recognition sequences for TEAD transcription fac-
tors, downstream mediators of YAP/TAZ activation in CAFs 
(Calvo et al., 2013) and AP1 family coregulators (Zanconato 
et al., 2015), and SPIB, an ETS family member (Schotte et al., 
2004; Dontje et al., 2006).
In contrast to stress responses, the role of ATF3 under 
basal conditions is much less studied. The mouse gene dele-
tion studies indicated that low levels of Atf3, like Csl, are also 
involved in negative control of CAF effector genes. In fact, 
up-regulation of these genes was not limited to mouse der-
mal fibroblasts but was also observed with several HDF strains 
of independent origin upon Atf3 gene silencing (Fig. 4 A). 
Genes such as Il6, Il8, Ptgs2 (Cox2), Acta2 (αSma), Tgfb2, 
Csf1, Tnc, and Postn, suppressed by increased ATF3 expression 
(Fig. 3 A), were induced by its silencing (Fig. 4 A). Concom-
itantly, positive regulators of CAF effector gene expression 
such as specific AP1 family members and TEAD transcription 
factors were up-regulated (Fig. 4, B and C).
For global assessment, two HDF strains with and with-
out ATF3 silencing were analyzed by RNA-seq. Several gene 
families of significance related to development, cell adhesion, 
cell cycle, inflammation/immune response, and reproduc-
tion/sex hormone signaling were affected by both increased 
and suppressed ATF3 expression (Table S4). Other families of 
relevance related to Notch and Wnt signaling and EMT were 
selectively affected by silencing of the gene, consistent with all 
other evidence discussed later in the paper that ATF3 at basal 
levels fulfills a constitutive function not affected by increases 
of its expression (Table S4).
Results were extended by gene set enrichment analysis 
(GSEA; Subramanian et al., 2005). Using this approach, we 
found a highly significant correlation between up-regulated 
genes in HDFs with Atf3 versus Csl gene silencing (Fig. 4 D) 
and with gene signatures related to development/angio-
genesis and inflammation (Fig. 4 E and Table S5). Similarly 
up-regulated genes included many for growth factors/cyto-
kines, membrane proteins/receptors, signaling, and transcrip-
tion (Fig. 4 F). Significant correlation was also found between 
genes down-regulated by Atf3 versus Csl silencing, with fam-
ilies related to developmental pathways including Notch and 
Wnt signaling (Fig. S2 A and Table S5).
We further tested whether there was any detectable 
binding of low levels of ATF3 to specific target genes, which 
may account for observed changes in gene expression. Using 
ChIP-seq of HDFs under basal conditions, we found only 
133 peaks of ATF3 binding with statistical significance 
equal to that of CSL binding peaks, which mapped within 
128 Ensembl gene/transcript identifiers (Ens. ID: http ://
www .ensembl .org /info /data /ftp /index .html). 60 of these 
gene identifiers were also CSL targets (Fig.  4 G and Table 
S6). MEA showed, next to ATF3 binding sites, recognition 
sequences for possibly relevant transcription factors, including 
HIF1A and CREB1 (Fig. 4 H).
The Csl gene itself was among the direct ATF3 tar-
gets, which were, however, only slightly up-regulated or 
not significantly modulated by Atf3 silencing in various 
HDF strains. The other ATF3 target sites were within pro-
tein-coding genes of little-known functions with flanking 
or embedded lncRNAs, pseudogenes, and miRNAs and/or 
consisted exclusively of noncoding sequences (Table S6). In-
terestingly, however, ATF3 binding was within 0.2–2 Mb of 
several genes of relevance, such as Il6 and Tead4, a finding that 
was confirmed by ChIP assays with corresponding specific 
primers in two other HDF strains different from those ana-
lyzed by ChIP-seq (Fig. S2 B).
convergent control of chromatin configuration by 
endogenous AtF3 and cSL
ATF3 functions in association with various chroma-
tin-modifying enzymes, and loss of ATF3 at specific bind-
ing sites may result in altered chromatin configuration even 
of loci at a large distance. To assess this possibility, we per-
formed ChIP-seq analysis of HDFs with and without Atf3 
gene silencing for specific histone modifications (H3K27ac, 
H3K27me3) and RNA polymerase II (Pol II) recruitment. 
We used the Integrative Genomics Viewer (IGV; Thor-
valdsdóttir et al., 2013) to visualize the ChIP-seq peaks in 
HDFs with and without silencing of Atf3 or Csl, individu-
ally and in combination.
H3K27 acetylation is a general indicator of open chroma-
tin configuration. We found pronounced changes in H3K27ac 
levels at various regions along chromosomes upon silencing 
of ATF3, even at a very large distance from its binding sites 
(Fig. 5 A and Fig. S2, C and D). Interestingly, there was an inter-
mingling of increased and decreased H3K27ac binding peaks, 
The right panels are representative images of a highly differentiated versus dysplastic papilloma. (E-G) IF analysis of tumors and underlying tissue from 
Atf3+/+ versus −/− mice with antibodies (Abs) against the indicated proteins. (H) IF analysis and quantification of double-positive cells in vimentin and IL6 
expression in nontumor-bearing skin areas of Atf3−/− versus Atf3+/+ mice. n = 5 fields from two mice for each genotype, counting 40–100 vimentin-positive 
cells per field. Data are mean ± SEM, two-tailed unpaired t test, *, P < 0.05. (I) IF analysis of entire mouse back skin with Ab against TNC in the skin of 
Atf3−/− versus Atf3+/+ mice at tumor areas (bracketed by arrows). Additional representative images for D, H, and I are shown in Fig. S1 (F–H).
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which, at this resolution, could not be resolved. The H3K27ac 
changes caused by Atf3 silencing were strikingly similar to 
those resulting from Csl silencing, with concomitant silencing 
of the two genes having no obvious additive effects (Fig. 5 A).
We then “zoomed in” on genomic regions encom-
passing deregulated relevant genes that map within 2 Mb 
from ATF3 binding sites to include distal enhancer elements 
(Merkenschlager and Odom, 2013). As previously mentioned, 
Figure 2. Atf3 deletion in mouse dermal fibroblasts enhances tumorigenic behavior of keratinocyte-derived Scc. (A) RT-qPCR analysis of the 
indicated genes in multiple parallel cultures of primary dermal fibroblasts derived from either individual or pooled newborn Atf3−/− (n = 8) and Atf3+/+ 
(n = 5) mice. Values are expressed as log10 ratios in Atf3−/− versus Atf3+/+ cultures. Data are mean ± SEM, one-tailed one-sample t test, *, P < 0.05; **, P < 
0.005. (B) RT-qPCR analysis of the indicated genes in two different preparations of primary dermal fibroblasts from Atf3loxP/loxP mice at 3 d after infection 
with a Cre-expressing adenovirus (Ad-Cre; n = 2) or GFP control (Ad-GFP; n = 2) for Atf3 gene deletion. In both experiments, Atf3 expression was reduced 
more than 40-fold in Ad-Cre–infected cells. Values are expressed as log10 ratios in cultures with and without Atf3 deletion. One-tailed, one-sample t test, 
*, P < 0.05. (C and D) Human SCC13 cells (DsRed) were admixed with mouse dermal fibroblasts (MDFs) with and without Atf3 deletion labeled with the 
PKH67 dye (green) followed by parallel ear injections into NOD/SCID mice. (C) Representative live images of a mouse pair injected with the combinations 
of cells 10 and 20 d after injection. (D) Quantification of red fluorescence signal (intensity × surface area) corresponding to SCC13 cell expansion. n = 4 
lesions per condition, mean ± SEM, two-tailed paired t test, *, P < 0.05. (E) H&E staining of ear lesions formed by SCC13 cells injected with dermal fibroblasts 
with and without Atf3 deletion. (F) Quantification of phospho-histone 3 (pH3)–positive DsRed2-SCC13 cells in mouse ear lesions. n = 4 fields per lesion, at 
least 200 cells per field; mean ± SEM, two-tailed unpaired t test, *, P < 0.05; **, P < 0.005. (G) IF analysis of mouse ear lesions with Ab against MMP1 using 
DsRed2 fluorescent signal for SCC cell identification. (H) Representative images of IF analysis of ear lesions with Ab against CD31 (left panels), together with 
quantification of the total blood vessel area per field (μm2) of three pairs of ear lesions using ImageJ software (right panel). n = 4 (for mouse 1) and n = 5 
(for mice 2 and 3) fields per lesion, mean ± SEM, two-tailed unpaired t test, *, P < 0.05. Additional representative images for E–G are shown in Fig. S1 (I–K).
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Figure 3. Induced Atf3 suppresses cAF effector genes with large overlap of binding targets with cSL. (A) Several HDF strains infected with a lenti-
viral vector for Doxycycline (Dox)–inducible Atf3 expression (pInd-Atf3; n = 3) versus empty vector control (pInd-Ctr; n = 2) were analyzed with and without 
Dox treatment (750 ng/ml for 3 d) for expression of the indicated genes. Values are expressed as ratio log10 (pInd-Atf3/pInd-Ctr), two-tailed, one-sample t 
test, *, P < 0.05, **, P < 0.005. (B) Overlap between ChIP-seq and RNA-seq profiles of genes bound and modulated by increased ATF3 expression in HDFs and 
those previously identified to be bound and controlled by CSL (Procopio et al., 2015). A complete list of genes is provided in Table S1. (C) GeneGo MetaCore 
analysis was performed with the data set of common direct target genes regulated by induced ATF3 and CSL. Shown is a list of process networks with 
statistically significant enrichment (P < 0.05). The complete list is provided in Table S2. (D) Representative list of common directly regulated genes by ATF3 
and CSL divided by biological function. (E) Schematic representation of induced ATF3 (orange arrows) and CSL (turquoise arrows) binding peak positions for 
four genes commonly targeted and regulated by induced ATF3 and CSL listed in D. Coding exons are shown as black squares, and the directions of the tran-
scription start sites are shown as black arrows. A complete list of induced ATF3 and CSL binding peak positions is provided in Table S3. (F) Motif enrichment 
analysis of nucleotide sequences surrounding elevated ATF3 and CSL binding peaks was performed by the RSAT peak-motifs tool. The number of ATF3 or 
CSL binding peaks with at least one predicted site of the indicated transcription factors is indicated along with the corresponding frequency (percentage).
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Figure 4. overlapping transcription repressive function of low levels of AtF3 and cSL. (A) RT-qPCR analysis of CAF effector genes in several inde-
pendent strains of HDFs (strain 1 tested twice at different passages) with and without Atf3 silencing by two different siRNAs (no. 1 and no. 2), using 36β4 
for normalization. n (HDF strains) = 8 siAtf3 no.1 and 2; 4 control siRNA. Values in A–C are expressed as log2 ratios (Atf3 siRNA/control siRNA), one-tailed, 
one-sample t test, *, P < 0.05; **, P < 0.005. (B) RT-qPCR analysis of AP1 family genes in independent HDF strains. n = 6 (siAtf3 no. 1 and 2), n = 3 (control 
siRNA). (C) RT-qPCR analysis of TEAD family members in independent HDF strains (strain 1 tested twice at different passages). n (HDF strains) = 6 siAtf3 no.1 
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the coding region for the Tead4 transcription factor lies within 
0.2 Mb of an ATF3 binding site on chromosome 12. ATF3 
silencing resulted in a substantial increase of H3K27ac at sev-
eral proximal regions of the Tead4 locus and at its transcrip-
tion start site, to which Pol II recruitment was also enhanced 
(Fig. 5, B and C). Increases in H3K27ac and Pol II recruitment 
were similar in HDFs with Csl gene silencing (Fig. 5 C).
Among CAF effector genes, Il6 also maps within 2 Mb 
of an ATF3 binding site. Even in this case, silencing of the 
Atf3 and Csl genes caused similar pronounced changes of 
H3K27ac and Pol II recruitment at the promoter region 
(Fig. 5, B and C). This similarity of the effects was also found 
for other transcription regulatory or CAF effector genes with 
altered expression in HDFs with and without Atf3 silencing 
located far away from ATF3 binding sites (Fig. S3).
To directly assess whether ATF3 binding plays a specific 
cis-regulatory function for genes at a large distance, we focused 
on the Il6 locus and resorted to CRI SPR-mediated deletion 
of the ATF3 binding region located 2 Mb upstream (Fig. 6, 
A and B). Several independent HDF clones were confirmed 
to have undergone the expected deletion by genomic PCR 
and nucleotide sequencing of the flanking region (Fig. 6, B 
and C). RT-qPCR analysis of these clones showed that Il6 ex-
pression was significantly induced, whereas that of two other 
genes under ATF3 control, Tnc and Tead4, was marginally 
affected (Fig. 6 C). Consistent with these results, immunoflu-
orescence analysis showed up-regulation of IL6 protein levels 
in HDFs with deletion of the ATF3 binding site (Fig. 6 D).
BEt inhibitors suppress cAF effector genes, with overlapping 
impact with AtF3- and cSL-dependent gene transcription
To assess the translational significance of the findings, we 
tested the impact of pharmacological inhibitors of BET pro-
teins, which link acetylation of histones and other proteins 
and the basal apparatus (Wang and Filippakopoulos, 2015). 
Treatment of two different HDF strains with silenced Atf3 
with the BET inhibitor JQ1 suppressed expression of all CAF 
marker genes (Fig. 7 A) and positive regulators of CAF gene 
expression such as TEAD transcription factors and cJun, JunB, 
and Fosl2 (Fig. 7 B). Expression of other AP1 family mem-
bers was less uniformly suppressed, and JunD was induced 
(Fig. 7 B). Treatment with JQ1 and iBET-762 and OTX-015, 
two compounds with similar activity in clinical trials (Filippa-
kopoulos and Knapp, 2014), down-modulated all tested CAF 
effector genes in several SCC-derived CAF strains (Fig. 7 C) 
in parallel with regulators of CAF gene expression, including 
various TEAD and AP1 family members; however, JunD, as in 
HDFs, was induced (Fig. 7 D).
BET inhibitors are not ubiquitous inhibitors of gene 
expression but exhibit gene- and cell-type specificity that can 
be of therapeutic interest (Filippakopoulos and Knapp, 2014). 
In fact, JQ1 treatment of SCC13 cells exerted differential ef-
fects on expression of three key proinflammatory genes: Il6 
was suppressed, Il8 was inhibited at low concentrations and 
induced at high concentrations, and Ptgs2 (Cox2) was un-
affected (Fig. 7 E). Importantly, JQ1 treatment of SCC cells 
caused strong induction of squamous differentiation markers, 
such as Keratin-1 (K1) and Loricrin (Lor), and CDK inhibi-
tors, such as Cdkn1a and Cdkn2b, in parallel with flattening 
and enlargement of cells and slowed proliferation (Fig. 7, E–G).
Significant differences are likely to exist among CAFs 
of various tumor types (Erez et al., 2010). JQ1 treatment was 
recently reported to suppress CAF effector genes in stromal 
fibroblasts of pancreatic ductal adenocarcinomas, with inhibi-
tion of SHH and TGF-β signaling as the underlying mech-
anism (Yamamoto et al., 2016). An important question was 
to what extent the BET inhibitor effects that we found with 
skin SCC-derived CAFs are linked to ATF3 and/or CSL 
control of gene expression versus those other pathways. We 
addressed this question using RNA-seq analysis of three dif-
ferent strains of CAFs with and without JQ1 treatment (Table 
S7), followed by comparative GSEA against various gene ex-
pression signatures. We found a highly significant positive 
correlation between genes down-modulated by JQ1 treat-
ment and by enhanced Atf3 expression (Fig. 7 H and Table 
S8), with a similarly significant inverse correlation with genes 
up-regulated by either Atf3 or Csl gene silencing (Fig. 7, I 
and J; and Table S8). Closely related process networks and 
functionally overlapping sets of genes were found in all these 
cases (Table S8). There was also a very significant correlation 
between genes down-modulated by JQ1 treatment and a set 
of 165 CAF signature genes (Table S9), bearing on various as-
pects of CAF activation (Fig. S4 A). Consistent with previous 
studies (Brown et al., 2014; Zou et al., 2014), we also found 
a statistically significant correlation between JQ1-modulated 
genes and two NF-κB–related gene sets, one from a study 
with HDFs (Hinata et al., 2003) and another as a common 
signature from multiple studies (for the noncanonical path-
and 2; 3 control siRNA. (D) Plot for gene set enrichment analysis (GSEA) using RNA-seq expression profiles of two HDF strains with and without silencing 
of Atf3 by two different siRNA against genes up-modulated in HDF by Csl silencing (Procopio et al., 2015). Genes are ranked by signal-to-noise ratio based 
on their differential expression in control versus ATF3-silenced HDFs; position of genes in the CSL gene set is indicated by black vertical bars, and the en-
richment score is shown in green. (E) List of significantly affected process networks (P < 0.05) as identified by GeneGo MetaCore analysis of genes within 
the core enrichment resulting from GSE analysis in D. The complete list is provided in Table S5. (F) List of representative genes within the core enrichment 
of GSE analysis in D divided by biological function. (G) Venn diagram illustrating the number of Ensembl gene/transcript identifiers (Ens. ID) bound by 
endogenous ATF3 and CSL in HDFs, as identified by ChIP-seq analysis with anti-ATF3 Ab of HDFs under basal conditions in comparison with the previously 
obtained ChIP-seq binding profile of endogenous CSL (Procopio et al., 2015). A complete list of binding peaks and corresponding genes is provided in Table 
S6. (H) Motif enrichment analysis of nucleotide sequences surrounding endogenous ATF3 binding peaks using the RSAT peak-motifs tool. The number of 
ATF3 binding peaks with at least one predicted site of the indicated transcription factors is indicated, along with the corresponding percentage.
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Figure 5. Atf3 and csl gene silencing cause similar overlapping changes in global chromatin configuration. ChIP-seq analysis of histone marks 
(H3K27ac and H3K27me3) and RNA Pol II in HDFs upon siRNA-mediated silencing of Atf3 and Csl compared with the scrambled siRNA control. (A) Difference 
in H3K27 acetylation along the length of two representative chromosomes (CHR 1 and 7) in HDFs with silencing of Atf3 (siAtf3) and Csl (siCsl), individually 
and in combination (siAtf3 and Csl) relative to control cells (siCtrl). The approximated location of individual CAF-related genes and endogenous ATF3 binding 
position as assessed by ChIP-seq are shown below the chromosomal maps. Individual patterns of H3K27ac along the length of the two chromosomes in A 
are shown in Fig. S2 C. Differences in H3K27ac for the other two chromosomes (CHR 2 and 4) are shown in Fig. S2 D. (B) Changes in H3K27 acetylation and 
trimethylation together with Pol-II recruitment caused by Atf3 silencing at genomic loci encompassing endogenous ATF3 binding sites and flanking Tead4 
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way; Fig. S4 B). In contrast, there was no correlation with 
either SHH or TGF-β gene sets such as would have been 
predicted on the basis of the previously mentioned study with 
pancreatic CAFs (Fig. S4 C; Yamamoto et al., 2016).
BEt inhibitors induce Scc differentiation and suppress cAF 
activation by in vivo topical treatment
The aforementioned results suggested that BET inhibitors 
can exert dual beneficial effects in vivo by suppressing CAF 
activation as well as inducing squamous cancer cell differen-
tiation. As these compounds exert systemic effects of possible 
concern for treatment (Filippakopoulos and Knapp, 2014), 
we tested whether they could be used topically using the 
ear injection assays described previously to assess behavior of 
SCC13 cells admixed with CAFs. In a first experiment, cells 
were injected 24 h before topical treatments with JQ1 in par-
allel with vehicle alone for 1 wk. In a second experiment, 
previously established ear lesions were treated with the BET 
inhibitor or vehicle for 1 wk. In both cases, the short time of 
treatment was not sufficient to affect tumor size. However, his-
tological and immunofluorescence analysis showed enhanced 
squamous cell differentiation in JQ1-treated tumor lesions in 
parallel with decreased cancer cell proliferation (Fig. 8, A and 
B; and Fig. S5, A–D). LCM of stromal fibroblasts (identified 
by IF with anti-PDG FR-α antibodies) and RT-PCR analysis 
showed down-modulation of Il6 and Ptgs2 (Cox2) expres-
sion using JQ1 treatment (Fig. 8 C), which was paralleled by 
decreased α-SMA and tenascin C (TNC) marker expression 
and reduced angiogenesis (as assessed by anti-CD31 staining; 
Fig. 8, D–F; and Fig. S5, E and F).
The impact of this compound on cancer stromal cells was 
further validated by analysis of explants of surgically excised 
skin SCCs. As shown in Fig. S5 (G and H), immunofluores-
cence analysis showed that IL6 and MMP1 were significantly 
reduced in stromal cells of tumor explants treated with JQ1.
dIScuSSIon
Conversion of stromal fibroblasts into CAFs can play a primary 
role in tumor initiation and progression. Several transcription 
regulatory pathways have been implicated in CAF activation, 
but the level at which they converge and control each other is 
mostly unknown (Junttila and de Sauvage, 2013; Dotto, 2014). 
More importantly, the involvement of chromatin reorgani-
zation and epigenetics modification in this context remains 
to be investigated. This has significant translational potential 
given the increasing number of compounds developed to tar-
get the epigenome, which could be used for preventing and/
or reverting CAF activation. We have found that as it is already 
at low basal levels, ATF3 converges with CSL in negative con-
trol of a large battery of CAF-determining genes through 
maintenance of chromatin configuration. BET-targeting 
compounds that unlink activated chromatin from the basic 
transcription apparatus counteract up-regulation of all these 
genes, with an impact on clinically derived CAFs amenable to 
in vivo topical treatment.
In contrast to its acute induction by acute UVA ex-
posure, we have found that basal expression of Atf3 is con-
sistently down-modulated in the stromal compartment of 
photo-damaged skin of premalignant keratinocyte lesions, 
possibly as a result of epigenetic modifications that also lead 
to compromised Notch2/Csl expression (Hu et al., 2012; 
Procopio et al., 2015). Functionally, loss or down-modulation 
of Atf3, as of Csl, led to induction of CAF activation, whereas 
increased Atf3 levels exerted opposite effects. This is consis-
tent with a model whereby induction of Atf3 expression plays 
a role in dampening the impact of acute proinflammatory 
and cell-damaging signals on dermal fibroblasts, whereas per-
sistent down-modulation of the gene promotes acquisition of 
proinflammatory and cancer-promoting properties.
Senescence of stromal fibroblasts with associated induc-
tion of CAF effector genes has been implicated in increased 
cancer risk with age (Campisi et al., 2011; van Deursen, 
2014). However, CAFs around established tumors often 
show increased proliferation rather than senescence (Junttila 
and de Sauvage, 2013; Polanska and Orimo, 2013). We pre-
viously showed that CSL functions as a link between con-
trol of senescence- and CAF-determinant genes, with loss of 
Csl function and escape from p53-dependent senescence as a 
two-step process required for full CAF activation (Procopio 
et al., 2015). Interestingly, ATF3 is also involved in the control 
of fibroblast proliferation, which we found to be decreased 
by Atf3 deletion or silencing and enhanced by increased Atf3 
expression. Although Atf3 expression is decreased in stromal 
fibroblasts adjacent to premalignant keratinocyte lesions, it is 
possible that as suggested by Buganim et al. (2011), its ex-
pression is increased during the later steps of CAF activation. 
In this case, however, additional genetic and/or epigenetic 
mechanisms are most likely required to prevent ATF3 from 
suppressing CAF effector genes involved in the enhance-
ment of tumor formation.
In HDFs, ATF3 at higher levels binds to a significant 
number of genes in common with CSL, suppressing their 
transcription. The most surprising finding was that, even at 
low basal levels, ATF3 plays an essential role in the negative 
and Il6 genes. Peaks of histone modification or Pol-II present in control HDFs (siCTRL) are shown in pink, peaks in HDFs with Atf3 gene silencing (siAtf3) are 
shown in turquoise, and overlapping areas present in both cells are shown in purple. For each panel, the chromosomal locations of the shown loci and scale 
bars are depicted at the bottom and top, respectively. Positions of ATF3 binding sites (calculated by MACS; Table S6) are indicated by vertical black arrows, 
and their zoom-in binding peaks are shown in Fig. S3 B. Lower lines are transcribed and spliced regions (blue boxes = coding exons) as predicted by Ensembl, 
together with the position and direction of transcription start sites (horizontal arrows). (C) “Zoomed in” chromatin modifications of the Tead4 and Il6 loci 
corresponding to the boxed region in B. Individual profiles for each condition were visualized in IGV and merged using Adobe Photoshop.
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control of these genes, binding to a very restricted number of 
distant sites that encompass mostly nonprotein coding genes 
of unknown function. Noncoding RNAs have been impli-
cated in multiple pathologies through a variety of mecha-
nisms, including chromatin deregulation (Betancur, 2016). 
As a concurrent mechanism, down-modulation or loss of 
Figure 6. deletion of an AtF3 binding region 2 Mb 
upstream of the IL6 gene results in specific induc-
tion of IL6 expression. (A) Overview of the construc-
tion of a dual-guide RNA (gRNA)–Cas9 expression vector. 
A two-step PCR amplification followed by insertion into 
the lentiCRI SPR_v2 vector backbone was used to create 
a dual-expression cassette with mouse (mU6) and human 
(hU6) U6 promoters driving expression of two gRNAs tar-
geting the ATF3 binding region upstream of the Il6 locus. 
For details, see Materials and methods. (B, top) Schematic 
representation of ATF3 binding region 2.07 Mb upstream 
of the Il6 locus, with the position of the dual gRNAs 
(gRNA 1 and 2) chosen for CRI SPR/Cas9–mediated dele-
tion and of the two primers (P1 and P2) used for genomic 
PCR analysis. (B, bottom) Nucleotide sequence of the 
genomic locus targeted by the two gRNAs (blue and red, 
respectively) together with PAM motifs (bold lines); below 
are the nucleotide-sequencing results of 300-bp genomic 
PCR products derived from two HDF clones expected 
to harbor the deletion (as shown in the panel below). 
(C) Small clusters/colonies of HDFs infected with the dual 
gRNAs lentiCRI SPR vector (▵) and empty vector control 
(C) were analyzed by genomic PCR analysis with the P1 
and P2 primers indicated above. Clones harboring the de-
letion in either a heterozygous or homozygous state, on 
the basis of PCR products of 300 bp versus 500 bp in size, 
were further analyzed by RT-qPCR for levels of Il6, Tnc, and 
Tead4 expression. (D) Two additional deletion-harboring 
clones were analyzed together with controls by IF with 
Ab against IL6 and TNC. Shown are representative images 
together with a quantification of the fluorescence inten-
sity signal in individual cells of deletion-harboring clones 
(▵) versus controls (C). n = 20 cells per condition, mean ± 
SEM, two-tailed unpaired t test, *, P < 0.0001.
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Figure 7. BEt inhibitors function as global suppressors of cAF gene transcription, with overlapping impact with AtF3- and cSL-dependent 
gene transcription. (A and B) Two independent HDF strains with Atf3 gene silencing by two siRNAs (no. 1 and 2) were treated 24 h after transfection with 
increasing doses of JQ1 (25, 100, and 500 nM) or DMSO vehicle for an additional 48 h. As a reference, a parallel set of cells was transfected with anti-Atf3 
siRNAs versus scrambled siRNA control. Expression of the indicated CAF effector (A) and positive regulator (B) genes was assessed by RT-qPCR. Results are 
shown as a heat map of ratios of gene expression (folds of down- or up-regulation in blue and magenta, respectively) in drug-treated versus DMSO control 
HDF and in cells with and without Atf3 silencing. (C) Three independent CAF strains from surgically excised skin SCCs were treated with increasing amounts 
(25, 100, and 500 nM) of three different inhibitors—JQ1, OTX-015 (OTX), and iBET 762 (iBET)—in parallel with DMSO alone for 48 h followed by RT-qPCR 
analysis of the indicated genes shown as a heat map plot. (D) CAF strains were treated with JQ1 (25, 100, and 500 nM) or DMSO control for 48 h, followed 
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the ATF3 transcriptional repressive complex is poised to 
cause site-specific chromatin modifications that can trigger a 
broader downstream cascade. Indicative of a cis-mode of reg-
ulation, CRI SPR-mediated deletion of a specific ATF3 bind-
ing region 2 Mb upstream of the Il6 gene caused induction of 
IL6 expression but did not affect other ATF3-regulated genes. 
Deregulation of chromatin regions around ATF3 binding sites 
extended to genes with roles in transcription/chromatin con-
trol, thus accounting for further chromatin modifications of 
chromosomal domains to which ATF3 does not bind. In fact, 
we found a striking overlap of H3K27 acetylation and RNA 
Pol II recruitment elicited by silencing of Atf3 and Csl at 
both chromosomal and individual gene levels. A similar chro-
matin profile was also observed in HDFs with concomitant 
down-modulation of Atf3 and Csl, pointing to a functional 
convergence of the two proteins with little or no additive 
effects resulting from their combined loss.
Compounds that interfere with CAF activation can 
be important for prevention as well as treatment of cancer 
(Goruppi and Dotto, 2013). Conversion of stromal fibroblasts 
into CAFs results from transcriptional up-regulation of a large 
battery of genes with multiple cellular functions, and several 
transcription regulatory pathways have been identified that 
control a subset of these genes, sometimes in an opposite 
manner (Kalluri and Zeisberg, 2006; Augsten, 2014; Dotto, 
2014). We have found that BET inhibitors are strikingly ef-
fective in suppressing expression of these genes, overcoming 
the effects of Atf3 or Csl gene silencing and exerting a specific 
impact on Atf3 and Csl gene expression signatures. Treatment 
of HDFs with these compounds caused marginal modulation 
of Csl and Atf3, placing the mechanism of action of BET 
inhibitors possibly downstream of these proteins.
It was recently reported that in the context of fibrotic 
conversion of liver stellate cells (Ding et al., 2015) or ras on-
cogene–induced senescence (Tasdemir et al., 2016), Brd4 si-
lencing exerted the same effects as the BET inhibitors. The 
BET inhibitors that we chose for our studies are acetyl–lysine 
mimetics that can cause Brd2, Brd3, and/or Brd4 proteins 
to release their partners (Filippakopoulos and Knapp, 2014). 
However, more complex mechanisms are possible, such as the 
reported chromatin association of BET inhibitors with sites 
of Brd protein occupancy (Anders et al., 2014).
Irrespectively of detailed mechanisms, we have shown 
that in parallel with their impact on CAFs, BET inhibitors 
can induce differentiation of squamous carcinoma cells, 
thus enhancing their potential therapeutic benefit. Despite 
encouraging phase I responses, safety concerns have been 
raised for the use of these inhibitors because of the possible 
unwarranted effects on metabolism or the immune system 
(Filippakopoulos and Knapp, 2014). These concerns would 
be bypassed by the topical application we have used. This ap-
proach could be of great interest for treatment of early pre-
cancerous and cancerous lesions originating in the skin and 
the surface of internal organs, coupled with methods to over-
come epithelia barrier functions.
MAtErIALS And MEthodS
cell/tissue explant preparation and treatments
Mouse dermal fibroblasts were prepared from individual or 
pooled newborn mice with homozygous disruption of the 
Atf3 gene (Hartman et al., 2004) versus littermate wild-type 
controls of the same genetic background (C57BL/68) or from 
newborn mice with the Atf3 gene flanked by loxP sites (Wol-
ford et al., 2013). Excised mouse back skin was immersed in 
0.25% trypsin–EDTA (Gibco) overnight at 4°C, and the der-
mis compartment was separated from the epidermis. Then, 
the dermis was minced and digested by collagenase I treat-
ment (0.4 mg/ml in HBSS [Ca2+ and Mg2+ free], Sigma- 
Aldrich) of the dermis for 30 min at room temperature with 
gentle agitation, followed by filtering through a 100-µm 
nylon mesh. After spinning, the cell pellet was resuspended 
and cultured in DMEM 10% FBS. For in vitro deletion of 
the Atf3 gene, dermal fibroblasts from Atf3loxP/loxP mice were 
infected with an adenovirus expressing Cre recombinase and 
GFP in parallel with a GFP-expressing control virus at mul-
tiplicity of infection of 100 for 8 h, which resulted in >99% 
of GFP-positive infected cells (Rangarajan et al., 2001). HDFs 
were prepared from discarded human skin samples from ab-
dominoplasty or circumcision at the Department of Surgery 
or Pediatrics, Lausanne University, with required institutional 
approvals and informed consent. Normal human skin sam-
ples and samples of SCCs were obtained at the Department 
of Dermatology, Massachusetts General Hospital, as discarded 
parts not needed for diagnosis. All samples were processed as 
approved by the institutional review board. After removal of 
subcutaneous adipose tissue, the skin was minced into small 
pieces and digested using 3% collagenase I (Sigma-Aldrich) in 
HBSS (Ca2+ and Mg2+ free) at 37°C for 1 h. After termination 
of enzymatic digestion by adding an equal volume of DMEM 
plus 10% FBS, cells were filtered through a 40-μm mesh, col-
by RT-qPCR analysis of the indicated CAF-positive regulator genes shown as a heat map plot. (E) SCC13 cells were treated with JQ1 at increasing amounts 
(25, 100, and 500 nM) versus DMSO vehicle alone for 48 h, followed by RT-qPCR analysis of the indicated genes and heat map plotting of the results. (F) 
Morphological changes induced in SCC13 cells by JQ1 treatment (500 nM) versus DMSO vehicle for 48 h. (G) Alamar blue cell density assays of SCC13 cells 
in triplicate wells treated with JQ1 at the indicated doses or DMSO alone, with daily measurements for 4 d. (H–J) Plot of gene set enrichment analysis (GSEA) 
using RNA-seq expression profile of three CAF strains with and without JQ1 treatment (500 nM for 2 d) versus vehicle (DMSO) against (H) set of genes 
down-modulated by induced ATF3, (I) set of genes up-regulated by siRNA-mediated Atf3 silencing, and (J) set of genes up-regulated by siRNA-mediated 
Csl silencing. Genes are ranked by the signal-to-noise ratio based on their differential expression in CAFs with JQ1 versus vehicle treatment; positions of 
the genes from the gene set are indicated by vertical bars, and the enrichment score is shown in green. The complete list of significantly enriched process 
networks (P < 0.05) identified by GeneGo MetaCore analysis for genes within the core enrichment resulting from GSEA analysis is provided in Table S8.
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Figure 8. topical BEt inhibitor treatment suppresses expression of cAF-determinant genes and promotes tumor squamous cell differentiation. 
DsRed2-expressing SCC13 cells admixed with one of the previously analyzed strains of CAFs (strain 2) labeled with the PKH67 dye (green) were injected 
into the ears of NOD/SCID mice, followed by topical treatment with JQ1 in ethanol (10.93 mM) or ethanol alone, daily for 1 wk, from 24 h after injection. 
In a second experiment, topical treatment with JQ1 in DMSO (10.93 mM) or DMSO vehicle alone initiated on the 17th day after injection, daily for 1 wk. (A) 
Macroscopic fluorescence images of an ear pair treated with JQ1 versus vehicle together with corresponding histological analysis at the end of the exper-
iment. (B) Mouse ear lesions from two experiments were analyzed by IF with Ab against the keratin-10 (K10), loricrin (Lor), and phospho-histone 3 (pH3), 
followed by quantification of the positive area (expressed as a percentage relative to the entire lesion size) by ImageJ software. n = 8 lesions per condition 
for K10 and Lor quantification, n = 6 lesions per condition for pH3 quantification; mean ± SEM, one-tailed paired t test. (C) LCM-captured PDG FRα-positive 
fibroblasts of ear lesions treated with JQ1 versus vehicle alone were analyzed by RT-qPCR for Il6 and Cox2 (PTGS2) expression. n = 6 lesions per condition, 
ratio log10 (JQ1/vehicle), two-tailed, one-sample t test. (D) Immunohistochemical staining with Ab against α-SMA of three different pairs of mouse ear 
tissues (first two pairs from the first experiment and the last pair from the second experiment). (E) IF analysis with Ab against TNC on JQ1-treated versus 
control lesions, followed by quantification of positive areas by ImageJ software. n = 8 lesions per condition (first experiment in red, second experiment in 
blue), mean ± SEM, one-tailed paired t test. (F) IF analysis with Ab against the CD31, followed by quantification of positive total blood vessel area per field 
(in square inches) in three different fields per lesion using ImageJ software. n = 6 lesions per condition (first experiment in red, second experiment in blue), 
mean ± SEM, one-tailed paired t test, *, P < 0.05; **, P < 0.005; ***, P < 0.0005. The first experiment is indicated in red, and the second experiment is indicated 
in blue. Additional representative images for A, B, E, and F from another mouse ear pair are shown in Fig. S5 (A–F). (G) Summarizing scheme: convergent role 
of ATF3 and CSL in negative control of CAF effector genes, with BET inhibitors exerting opposite effects of ATF3 and CSL loss in CAF activation.
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lected by centrifugation (1,500 rpm for 5 min), plated, and 
cultured in DMEM plus 10% FBS until 60–70% confluency 
before passage. CAF strains were derived from surgically 
excised skin SCCs obtained from the Department of Der-
matology, Massachusetts General Hospital, with institutional 
approval and informed consent as required. Skin SCC samples 
were cut in 1- to 2-mm pieces after removal of fat excess, 
followed by incubation in 2 ml of PBS containing 0.25 mg/
ml of Liberase TL (Roche) for 40 min at 37°C with gentle 
shaking. After terminating the enzymatic digestion, the disso-
ciated tissue was passed through a 10-ml syringe attached to 
a 70-μm sieve. Cells from the flowthrough were centrifuged, 
washed three times with DMEM plus 10% FBS, and seeded in 
a 10-cm tissue culture dish. Adherent cells were expanded for 
characterization as with HDFs. Normal skin and skin SCC 
explant cultures were prepared from discarded human skin 
samples obtained from the Department of Surgery or Pediat-
rics, Lausanne University, and from surgically excised human 
skin SCCs obtained from the Department of Dermatology, 
Massachusetts General Hospital, with institutional approval 
and informed consent as required. Skin samples sterilized in 
70% ethanol and cut after removal of subcutaneous fat into 
1 × 1–cm pieces were placed in DMEM supplemented with 
20% FBS and 1% MEM vitamin (Gibco) in a 0.25% semisolid 
agar medium (Sigma-Aldrich). The epidermis was maintained 
at the air–medium interface. For the UV treatment of HDFs 
or skin explants, we used a Bio-Link cross-linker UV irradi-
ation system (Vilber Lourmat) equipped with a UVA (375 
nm) lamp, with a portable photometer IL1400A (Interna-
tional Light Technologies) measuring for dosage determina-
tion. Cells or skin SCC explants were treated with indicated 
doses of JQ1 (Cayman Chemical), iBET-762 (MedChem Ex-
press), and OTX-015 (Active Biochem) dissolved in DMSO 
for 2 d (cultured cells) or daily for 5 d (SCC explants).
Skin SCC13 (Rheinwald and Beckett, 1981) and 
PAM212 (Roop et al., 1983) were originally reported 
and subsequently checked for the presence of oncogenic 
mutations (https ://cansar .icr .ac .uk /cansar /cell -lines /PAM212 /
mutations /; Wu et al., 2010).They have been routinely tested 
for mycoplasma and have not been authenticated for STR 
(short tandem repeat) profiling. None of the used human 
cell lines is listed in the NCBI BioSample Database of 
misidentified cell lines.
Genetic manipulations and gene expression analysis
Conditions for viral infection, shRNA- and siRNA-mediated 
gene silencing, and RT-qPCR were as follows. The pMXs-
Atf3 vector was prepared by inserting 543 bp of human ATF3 
cDNA into the Xho I site of the retrovirus vector pMXs-neo 
(Tamura et al., 2005; Wu et al., 2010). For doxycycline-in-
ducible Atf3 expression, the human Atf3 coding sequence 
was amplified from pMXs-Atf3 by PCR and cloned into a 
TOPO-pENTR vector, followed by transfer into 
pIND UCER20 (Meerbrey et al., 2011) using the Gateway LR 
recombinase system (Thermo Fisher Scientific). pMXs-Atf3 
and pIND UCER20 lentivirus were packaged in HEK293T 
cells and incubated with HDFs for 24 h. Cells were selected, 
respectively, with 500 μg/ml of G418 for 7 d and 1 μg/ml 
of puromycin for 5 d for pMXs-Atf3 and pIND UCER20- 
ATF3 2 d after selection. For the siRNA experiment, HDFs 
were transfected with 20 nM siRNA (Invitrogen) using 
INT ERF ERin reagent (Polyplus) for 12 h according to the 
manufacturer’s recommendation. HDFs were collected for 
RT-qPCR analysis 3 d after siRNA transfection, 9 d after 
constitutive Atf3 expression (pMXs-Atf3), 3 d after doxycy-
cline (750 ng/μl)–inducible Atf3 expression (pIND20-ATF3), 
and 3 d after Cre-expressing adenovirus infection. HDFs with 
Atf3 gene silencing were treated with JQ1 for 2 d after 1 d 
of Atf3 siRNA transfection. 1 µg of total RNA was used to 
reverse transcribe cDNA using RevertAidH Minus Reverse 
transcription (Thermo Fisher Scientific) followed by real-time 
qPCR using the SYBR Fast qPCR master mix (Kapa Bio-
systems) in the Light Cycler 480 (Roche) according to the 
manufacturer’s protocols. All RNA samples were analyzed in 
triplicate with gene-specific primers and 36β4 normalization 
for human samples and Gapdh for mouse samples. The list of 
siRNAs and RT-qPCR primers is provided in Table S10.
crI SPr/cas9-mediated deletion of the AtF3 binding site
The endogenous ATF3 binding region 2.07 Mb upstream 
of the Il6 locus—as determined by the ChIP-seq analysis 
provided in Table S6—was deleted using a dual-guide RNA 
CRI SPR/Cas9 gene editing strategy (Fig. 6 A). Specifically, 
two guide RNAs (gRNA 1 and 2) encompassing this 
region (listed in Table S10) were identified using the MIT 
(Massachusetts Institute of Technology) CRI SPR design tool 
(http ://crispr .mit .edu). A lentiviral vector with a double CRI 
SPR cassette and Cas9 expression was constructed, starting 
from lentiCRI SPR_v2 (Addgene, 60954) using the following 
steps: (a) the mouse U6 (mU6) promoter was PCR amplified 
with a forward primer also containing an upstream scaffold 
and a terminator sequence (mU6 scaff/ter Fwd) and a reverse 
primer corresponding to the 3′ end of the mU6 sequence 
(mU6 Rev); (b) the PCR product was subjected to a second 
round of PCR with a forward primer containing the gRNA 
1 sequence (gRNA_1 Fwd) preceded by a BsmBI recognition 
sequence and a reverse primer with the gRNA 2 sequence 
(gRNA_2 Rev) followed by a BsmBI recognition sequence; 
(c) the PCR product was then digested with BsmBI to 
generate compatible sticky ends and ligated into the BsmBI 
sites located between the human U6 (hU6) promoter and 
scaffold sequence of lentiCRI SPR_v2 using NEB Quick 
Ligase (New England Biolabs, Inc., M2200). A control ‘empty’ 
lentiCRI SPR_v2 vector lacking any gRNAs was generated 
by BsmBI digestion followed by blunt-end ligation.
The dual gRNAs lentiCRI SPR vector and empty vec-
tor control were used for viral production and infection of 
low-passage HDFs. 48  h later, infected cells were diluted, 
seeded in limited numbers, and subjected to puromycin (2 
μg/ml) selection. Puromycin-resistant cells were allowed to 
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grow until they formed small clusters/colonies. Cells from 
individual clusters were collected for genomic PCR analysis, 
with primers flanking the targeted ATF3 binding site (listed 
in Table S10) using Q5 high-fidelity DNA polymerase (New 
England Biolabs, Inc., M0491). PCR products of the expected 
smaller deletion size were excised for nucleotide sequencing 
to confirm deletion. Replated HDF colonies carrying the 
deletion were analyzed in parallel with colonies without the 
deletion and/or infected with the lentiCRI SPR empty vec-
tor control by qRT-PCR analysis or by IF with anti-IL6 and 
anti-TNC antibodies (Table S11).
tumorigenesis experiments
Mice with homozygous disruption of the Atf3 gene (Hart-
man et al., 2004) and wild-type controls in the same genetic 
background (C57BL/68; 8 wk old, Charles River) were sub-
jected to a skin carcinogenesis protocol (Topley et al., 1999), 
with a single topical application of 7, 12-Dimethylbenz[a]
anthracene (DMBA; 20 μg in 200 μl acetone) followed by 
biweekly treatments with 12-O-tetradecanoylphorbol 13-ac-
etate (TPA; 10−4 M in acetone) for 25 wk. Tumors larger than 
3 mm2 were analyzed and classified by histology: highly dif-
ferentiated papillomas (differentiation >50% of tumor vol-
ume), moderately differentiated papillomas, dysplastic tumors 
with penetration into superficial dermis, and fully invasive 
SCC, with tumor invasion into the panniculus carnosus.
Intradermal ear injection assays and live imaging were 
performed as follows. Mouse dermal fibroblasts with and 
without Atf3 deletion labeled with PKH67 (Sigma-Aldrich) 
were admixed in equal numbers (105 cells per injection), with 
SCC13 cells stably infected with a DsRed2-expressing lenti-
virus. To minimize individual animal variation, the two com-
binations of cells were injected in parallel into the left and 
right ears of mice (8 to 12 wk old NOD/SCID, IL-2 recep-
tor gamma chain negative (Il2rg−/−). Mice were sacrificed 3 
wk later for tissue analysis. Quantification of red fluorescence 
signal (intensity × surface area) corresponding to SCC13 cell 
expansion was obtained by ImageJ software analysis of dig-
itally acquired images and expressed, at each time point, as 
relative to the initial signal 24 h after cell injection. Quantifi-
cation of stromal cell expansion by green fluorescence signal 
yielded uneven results, due in some cases to disappearance of 
the lipid dye staining. For in vivo JQ1 assays, similar ear injec-
tions were performed with DsRed2-expressing SCC13 cells 
admixed with clinically derived CAFs (strain 2) labeled with 
PKH67. 1 or 17 d after injection, mice were treated topically, 
on the left and right ears, respectively, with JQ1 (100 μg in 20 
μl of ethanol or DMSO) or vehicle alone daily for 1 wk. For 
both assays, cells were loaded into a 33-gauge microsyringe 
(Hamilton) in 3 μl of sterile HBSS. Live images were acquired 
with a fluorescence stereomicroscope (Leica M205F) every 
2–3 d. ImageJ Lasso Toll was used for quantification of red 
and green fluorescence signal (intensity × surface area).
Back skin intradermal tumorigenicity assays were per-
formed by admixing mouse dermal fibroblasts with and 
without Atf3 deletion (106 cells per injection) with weakly 
transformed mouse Pam212 keratinocyte line or SCC13 cells 
(2 × 106 cells per injection). To minimize individual animal 
variation, mice (NOD/SCID) were injected in parallel, in 
the left and right flanks, respectively, with the two combina-
tions of cells. Mice were sacrificed 4 wk later for tumor tissue 
retrieval and analysis.
All mouse work was performed according to the Swiss 
guidelines and regulations for the care and use of labora-
tory animals, with approved protocol from the Canton de 
Vaud veterinary office.
tissue analysis
LCM with an Arcturus XT microdissection system (Applied 
Biosystems) was performed as follows. Frozen tissue sections 
were cut in 8 μm slices and mounted on membrane-coated 
glass slides (LCM522, Applied Biosystems). After staining in 
1% methylene green in DEPC (diethyl pyrocarbonate) water 
for 10 s and washing three times in DEPC water, sections were 
immediately used for microdissection. Each capture was col-
lected from the membrane and transferred to a TRI reagent 
(Sigma-Aldrich), and RNA was extracted using a standard 
protocol with additional proteinase K and DNase I treatment. 
For immunofluorescence-guided LCM, fresh frozen block 
sections were briefly incubated with fluorescein isothiocy-
anate (FITC)–conjugated antibody against PDG FRα (Santa 
Cruz Biotechnology, Inc.) and propidium iodide for 30 s. For 
RNA extraction, an Arcturus PicoPure RNA isolation kit 
(Applied Biosystems) was used according to the manufactur-
er’s recommendations. Primers used for RT-qPCR are listed 
in Table S10. Conditions for IF and immunohistochemistry 
were as follows. Sections were fixed in 4% paraformaldehyde 
(PFA) and permeabilized in 0.5% Triton X-100 in PBS fol-
lowed by blocking in 5% donkey serum. Primary antibodies 
were stained at 4°C overnight; secondary antibodies were in-
cubated at room temperature for 2 h and mounted in Fluo-
romount Mounting Medium (Sigma-Aldrich) after nuclear 
DAPI staining. Antibodies are listed in Table S11. Immuno-
fluorescence images were acquired with a ZEI SS LSM510 or 
ZEI SS LSM700 Meta laser scanning.
For fluorescence signal quantification, acquired im-
ages for each color channel were imported into either 
Adobe Photoshop software, followed by Lasso Tool selec-
tion, or ImageJ software, using the functions “measurement” 
or “particle analysis” for selection of areas or cells (tumor 
or stromal) of interest. All measurements were exported as 
Microsoft Excel data files.
rnA-seq and GSEA
RNA-seq analysis was performed as follows. Total RNA was 
extracted 3 d after siRNA transfection for ATF3 knockdown 
samples and 3 d after doxycycline treatment for ATF3 over-
expression samples using the directZol RNA miniprep kit 
(Zymo Research) with on-column DNase treatment. RNA 
quality was verified on the bioanalyzer (Agilent Technolo-
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gies) with an RNA integrity number greater than 8. Four 
μg of total RNA was used for library preparation using the 
Truseq kit (Illumina). A single read was done on the Illumina 
HiSeq 2000 sequencer at the Genomic Technologies Facility 
at the University of Lausanne. Reads were trimmed using 
Trimmomatic (version 0.22) and then mapped to the human 
hg19 reference genome using TopHat (version 2.0.8b). 
Gene expression levels were evaluated using the HTSeq 
package (release 0.5.4p1).
GSEA for RNA-seq expression profiles was conducted 
using the software GSAA-seqSP (gene set association analysis 
for RNA-seq data with sample permutation; Xiong et al., 
2014) from the GSAA platform (version GSAA_2.0, http 
://gsaa .unc .edu /) with default parameters. Curated gene 
sets were retrieved from the Molecular Signatures Database 
(MSigDB version 5.2, http ://www .broadinstitute .org /
gsea /msigdb /). The pathway gene sets used in this study 
are listed in Fig. S4 C.
chIP-seq, chIP tagmentation, and MEA
ChIP-seq analysis was performed as follows starting from 107 
HDFs for ATF3 and ∼5 × 106 HDFs for histone modification 
marks and RNA Pol II (the antibodies and concentrations 
used are listed in Table S10). Immunoprecipitated DNA using 
5 μg of antibodies per 106 cells was quantified by fluorometry 
on the Qubit system (Invitrogen). A total of 10 ng of ChIPed 
DNA was used for library preparation using the NEBNext 
ChIP-seq Library Prep Reagent Set for Illumina (New 
England Biolabs, Inc.) as recommended by the manufacturer. 
A Burrows-Wheeler Aligner (http ://bio -bwa .sourceforge 
.net) was used for FAS TQ file alignments, and MACS 
software (http ://liulab .dfci .havard .edu /MACS) with default 
parameters was used for peak detection.
All statistical analysis of ChIP-seq data was done 
using statistical computing R (version 3.2.2) and various 
Bioconductor packages (http ://www .Bioconductor .org). 
Raw FAS TQ sequences were aligned to the human reference 
genome (Ensembl release, version GRCh37) with the 
software BWA (version 0.7.12; Li and Durbin, 2009). Overall 
sequencing quality and absence of contaminants were assessed 
with the tool FASTqc (version 0.11.2, FAS TQC, http ://
www .bioinformatics .babraham .ac .uk /projects /fastqc /). 
Immunoprecipitation efficiency was assessed with the tool 
CHA NCE (version 2.0; Diaz et al., 2012), which showed a 
cumulative percent enrichment over input >25% in all ChIP-
seq samples, each relative to its own input.
ChIP-seq peaks with a false discovery rate and fold 
change enrichment relative to the background signal were 
identified with the peak caller software MACS (version 2.1; 
Zhang et al., 2008) used in treatment control mode with input 
as background for ATF3 binding; the peak model building 
mode was disabled for broad histone marker peaks using a 
global background signal.
To compare peaks in regions of interest across different 
samples, we generated signal tracks with MACS2. MACS2 
builds the signal track, computing the number of fragments 
found at each genomic position. These values are normal-
ized in millions of reads, to account for the library size, and 
stored in the bedGraph format. The bedGraph files were sub-
sequently converted to the bigWig format using the UCSC 
tool begGraphToBigWig (Kent et al., 2010). The advantages 
of this latter format are the reduced size and the presence of 
an index for faster access. The resulting tracks were visualized 
with IGV version 2.3.88 (Thorvaldsdóttir et al., 2013). For 
direct comparisons, the IGV subtract operator tool was used 
to combine two data tracks to generate and visualize sample 
differences. Individual profiles for each condition were visu-
alized in IGV and merged using Adobe Photoshop.
ChIP tagmentation (Schmidl et al., 2015) followed by 
quantitative PCR analysis was used for endogenous ATF3 
ChIP-seq data validation. Chromatin immune precipitation 
was carried from 4 × 106 HDFs as for the ChIP assay with 
anti-ATF3 antibody versus nonimmune IgGs. The bead-
bound chromatin was tagged with Tn5 transposase (Nextera 
DNA Sample Prep kit, Illumina). The “tagmented” chromatin 
was de-cross-linked, purified, and amplified (14 cycles) using 
tag-specific primers. The amplified products were diluted 
(1:10), and 1 μl was used as a template for qPCR to determine 
the enrichment of the indicated sites; the primer sequences 
and antibodies are listed in Tables S10 and S11, respectively.
MEA was conducted using Regulatory Sequence 
Analysis Tools (RSAT; Thomas-Chollier et al., 2012). The 
ATF3 peak coordinates in the bed format were uploaded 
onto the RSAT web server (http ://floresta .eead .csic .es 
/rsat /peak -motifs _form .cgi), and the fetched sequences 
were compared with the discovered motifs using JAS PAR 
CORE vertebrates databases.
Statistics
Data are presented as means or ratios ± SD or ± SEM among 
experimental groups and controls, as indicated in the figure 
legends. For gene expression and functional assays, statistical 
significance of differences between experimental groups and 
controls (as biological replicates) was assessed by one- or two-
tailed unpaired or paired t tests, one- or two-sided one-sam-
ple t tests, and two-tailed χ2 tests, as indicated in the figure 
legends. More specifically, a one-tailed t test was used when 
the null hypothesis was articulated directionally for compar-
isons of relatively large combinations of samples and genes 
(such as in Fig. 2, A and B; Fig. 4, A–C; Fig. 8, B, E, and F; 
Fig. S1, C, E, and N; and Fig. S5, G and H). Parametric tests 
were used without any assumption for data distribution, and 
variation within each group of data has not been estimated.
For ear injection and tumorigenicity assays, a sample 
size of adequate statistical power was ensured by minimizing 
the individual animal variability issue by parallel ear or back 
injections of the same animals with control versus experi-
mental combinations of cells.
No statistical method was used to predetermine sample 
size. No exclusion criteria were adopted for animal studies 
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and samples collection. No randomization was used, and the 
researchers involved in the study were not blinded during 
sample obtainment or data analysis.
Accession numbers
The RNA-seq and ChIP-seq data sets generated for this study 
were deposited in GEO as the GSE81406 super-series dataset.
reproducibility of experiments
For RT-qPCR in Fig. 2 (A and B), Fig. 3 A, Fig. 4 (A–C), 
Fig. 6 C, Fig. 7 (A–D), and Fig. S1 D, repeated experiments 
on several primary cell strains or culture preparations are 
shown as indicated in the corresponding figure legends.
Additional representative IF and H&E tissue-staining 
images for Fig. 1 (D and I), Fig. 2 (E and G), and Fig. 8 A are 
shown in Fig. S1 (F, H, I, and K) and Fig. S5 A, respectively.
In Fig. 1 H, Fig. 2 (C, F, and H), Fig. 6 D, Fig. 8 (B, 
E, and F), Fig. S1 (C, N, and O), and Fig. S5 (G and H), 
representative IF images are shown together with signal 
quantification from multiple samples as specified in the cor-
responding figure legends.
Findings in Fig. 2 (C–F) were validated by alternative in 
vivo approaches in two independent experiments with two 
different tumor cell lines, as shown in Fig. S1 (L–N).
Findings in Fig. 1 D and Fig. 8 (A–F) were obtained in 
two independent experiments.
For Fig. S1 A, similar results were obtained in Fig. S1 D 
in two independent experiments and further validated with 
different approaches, as shown in Fig. S1 (B and C).
online supplemental material
Fig. S1 shows that Atf3 deficiency promotes dysplastic kera-
tinocyte tumors and CAF activation. Fig. S2 shows that Atf3 
and Csl gene silencing cause similar changes in transcriptional 
profile and global chromatin configuration. Fig. S3 shows that 
Atf3 and Csl gene silencing cause similar chromatin changes 
at genomic loci to which endogenous ATF3 does not bind. 
Fig. S4 shows that JQ1-modulated genes are significantly cor-
related with NF-κB but not SHH or TGF-β signaling gene 
sets. Fig. S5 shows that BET inhibitor treatment promotes 
tumor squamous cell differentiation and suppresses expression 
of CAF-determinant genes in induced skin lesions and human 
skin SCC explants. Table S1 provides combined ChIP-seq and 
RNA-seq analysis of induced ATF3 and CSL in HDF. Table S2 
provides GeneGo MetaCore analysis of ATF3/CSL–regulated 
target genes identified by ChIP-seq and RNA-seq. Table S3 
provides the induced ATF3 and endogenous CSL binding peak 
positions on 102 common regulated target genes. Table S4 
provides the RNA-seq profiles of HDF with and without Atf3 
gene silencing. Table S5 provides GeneGo MetaCore analysis 
for GSEA of Atf3-silenced HDFs. Table S6 provides the ChIP-
seq profiles of endogenous ATF3 in HDF. Table S7 provides the 
RNA-seq profiles of CAFs with and without JQ1 treatment. 
Table S8 provides GeneGo MetaCore analysis for GSEA of 
JQ1-treated CAFs. Table S9 provides the CAF gene set used for 
GSEA. Table S10 provides the RT-qPCR primers, guide RNA, 
and siRNAs used in this study. Table S11 lists the antibodies 
used in this study. Tables S1–S11 are provided as Excel files.
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